Welcome to our dedicated page for ARPO news (Ticker: ARPO), a resource for investors and traders seeking the latest updates and insights on ARPO stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ARPO's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ARPO's position in the market.
Aerpio Pharmaceuticals (Nasdaq: ARPO) will host a webinar on November 12, 2020, featuring key opinion leaders discussing Tie2 activation for COVID-19 treatment. The call will spotlight razuprotafib, a novel Tie2 activator, aimed at reducing the severity of COVID-19 and its complications. The company is conducting two Phase 2 clinical trials, I-SPY COVID-19 and RESCUE, focusing on COVID-19 patients. Updates are expected in early 2021, emphasizing Aerpio's commitment to addressing COVID-19 and its impact on pulmonary and vascular health.
Aerpio Pharmaceuticals (Nasdaq: ARPO) plans to release its Q3 2020 financial results on November 10, 2020, before the market opens. The company is focused on developing Tie2 activating compounds for treating ocular diseases and diabetic complications, along with potential applications for acute respiratory distress syndrome (ARDS) linked to COVID-19. The conference call will begin at 8:30 AM ET, providing insights into financial performance and future developments.
Aerpio Pharmaceuticals (Nasdaq: ARPO) has initiated dosing in its Phase 2 clinical trial evaluating razuprotafib for preventing and treating acute respiratory distress syndrome (ARDS) in moderate-to-severe COVID-19 patients. This trial, supported partially by the U.S. military, complements the previously announced I-SPY COVID-19 trial focusing on critically ill patients. Razuprotafib aims to activate the Tie2 pathway, potentially benefiting COVID-19 patients and others with ARDS-related conditions. The company is also exploring razuprotafib's application for other diabetic complications.
Aerpio Pharmaceuticals (Nasdaq: ARPO) has completed patient enrollment for its Phase 2 trial examining the efficacy of razuprotafib for managing elevated intraocular pressure in glaucoma and ocular hypertension patients. This double-blind study involves around 195 participants over 28 days and tests razuprotafib against a latanoprost baseline. Results are expected in Q4 2020. The company believes razuprotafib could be a valuable adjunct therapy due to its novel action mechanism.
Aerpio Pharmaceuticals (ARPO) reported its Q2 2020 financial results, ending with $44.9 million in cash. The company has initiated a Phase 2 trial for razuprotafib in Open Angle Glaucoma, recruiting ahead of schedule with over 170 patients enrolled. Aerpio is also involved in the I-SPY COVID Trial, assessing razuprotafib for ARDS in COVID-19 patients. The company secured funding of up to $5.1 million for an additional ARDS trial. Q2 revenue reached $15 million, primarily from a license agreement, with a net income of $9.3 million.
Aerpio Pharmaceuticals (Nasdaq: ARPO) will release its Q2 2020 financial results on August 12, 2020, before market open, followed by a conference call at 8:30 AM ET. The biopharmaceutical company focuses on developing compounds activating Tie2 for ocular diseases, ARDS related to COVID-19, and diabetic complications. Key compounds include razuprotafib for open-angle glaucoma and ARP-1536 for diabetic vascular complications. The company also has a bispecific antibody targeting VEGF and VE-PTP for age-related macular degeneration.
Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO) is holding its 2020 annual meeting on June 24, 2020, at 10:30 a.m. ET, now in a virtual-only format due to COVID-19 safety concerns. Stockholders of record as of April 27, 2020, can participate and vote online. Guests can listen to the meeting but cannot vote or ask questions. Instructions for accessing the meeting and registering are provided, highlighting the importance of early registration for beneficial owners. Aerpio continues to focus on developing treatments for ocular diseases and diabetic complications.
Aerpio Pharmaceuticals (Nasdaq: ARPO) announced a key opinion leader call on June 12, 2020, to discuss a novel mechanism for glaucoma treatment. Expert presentations will be made by Dr. Paul Kaufman and Dr. Janey Wiggs, focusing on unmet medical needs in glaucoma and the Tie2 receptor's role in intraocular pressure management. The company's candidate, razuprotafib, shows promise in reducing intraocular pressure, having met positive results in a Phase 1b trial. The treatment is set to enter Phase 2 trials in Q3 2020, with top-line data expected in Q1 2021.
Aerpio Pharmaceuticals (Nasdaq: ARPO) announced a restructuring of its licensing deal with Gossamer Bio (Nasdaq: GOSS) for GB004, a HIF-1 alpha stabilizer. The agreement includes an immediate payment of $15 million and potential milestone payments totaling $90 million linked to regulatory approvals and sales. Additionally, Aerpio will receive tiered royalties on sales in the low to mid-single digits. The collaboration aims to leverage Gossamer's expertise in GI drug development to advance GB004, which targets inflammatory bowel disease.
Aerpio Pharmaceuticals (Nasdaq: ARPO) reported its Q1 2020 financial results on May 7, 2020. The company has $34.6 million in cash, down from $38.5 million at year-end 2019. Operating expenses decreased by 53.4% to $4.1 million, while R&D expenses fell by 67.3% to $1.8 million, reflecting reduced clinical program costs. The net loss for Q1 2020 was $3.9 million, or $0.10 per share, a significant reduction from a loss of $8.5 million, or $0.21 per share, in Q1 2019. Aerpio remains optimistic about its glaucoma program and plans to initiate a Phase 2 study in Q3 2020.
